Quince Therapeutics, Inc.
QNCX
$3.70
$0.329.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.44M | -16.05M | -15.03M | -12.46M | -5.49M |
| Total Depreciation and Amortization | 36.00K | 35.00K | 32.00K | 16.00K | 86.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.28M | 6.47M | 3.35M | 3.00M | -1.70M |
| Change in Net Operating Assets | 194.00K | -1.87M | 2.05M | 1.90M | -152.00K |
| Cash from Operations | -9.93M | -11.42M | -9.60M | -7.55M | -7.26M |
| Capital Expenditure | -74.00K | -126.00K | -148.00K | -133.00K | -46.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.71M | 6.17M | 11.05M | 11.00M | 7.15M |
| Cash from Investing | -1.78M | 6.04M | 10.90M | 10.87M | 7.11M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.38M | 14.41M | 87.00K | 0.00 | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -5.00M |
| Cash from Financing | 1.38M | 14.41M | 87.00K | 0.00 | -5.00M |
| Foreign Exchange rate Adjustments | -41.00K | 19.00K | 175.00K | 222.00K | -60.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.37M | 9.06M | 1.56M | 3.54M | -5.22M |